Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

KPV Peptide for Laboratory Research | Basic Information, Published Studies, COA Checks, and Handling

KPV Peptide for Laboratory Research: Basic Information, Published Studies, COA Checks, and Handling

Research Use Only — Laboratory Professionals Only: This article is for trained laboratory personnel. All concentrations, preparation notes, and study summaries apply only to controlled in-vitro research or standard mouse models.

Do not use this information for personal or home preparation, human administration, veterinary dosing, cosmetic use, food use, or any consumer application.

Basic Information

KPV is a three-amino-acid peptide with the sequence H-Lys-Pro-Val-OH. It is also called alpha-MSH (11–13) because it matches residues 11–13 of alpha-melanocyte-stimulating hormone in amino-acid order.

KPV Peptide for Laboratory Research丨Basic Information, Published Studies, COA Checks, and Handling

However, the free-acid form H-Lys-Pro-Val-OH is not terminally identical to native alpha-MSH, whose C-terminal valine is amidated (Val-NH2). PubChem lists the unmodified free-acid form under CID 125672, with CAS 67727-97-3, molecular formula C16H30N4O4, average molecular weight 342.43 g/mol (exact mass 342.22670545 Da), XLogP3 −3.5, topological polar surface area 139 Ų, four hydrogen bond donors, and six hydrogen bond acceptors.[1]

Item Information for free-acid KPV
Sequence H-Lys-Pro-Val-OH
CAS number 67727-97-3
Molecular formula C16H30N4O4
Molecular weight 342.43 g/mol (average); exact mass 342.22670545 Da
Purity Use the HPLC result on the lot-specific COA. Do not use one purity figure for every batch.
Storage The default instruction used in this article is −20°C, protected from light and moisture. The lot label and COA take priority if they give a different condition.
Solubility Check the lot information and run a small laboratory solubility test at the required concentration before preparing a full stock. A visually clear solution does not, by itself, prove identity, purity, stability, or that the intended concentration was reached.

The chemical form matters. PubChem lists KPV acetate separately under CID 90474670 (CAS 2828433-34-5), with molecular formula C18H34N4O6 and molecular weight 402.5 g/mol (exact mass 402.24783482 Da).

Free-acid and acetate values must not be mixed when calculating concentration or reading a COA.[2]

KPV must also be kept separate from KdPV, which contains D-proline. KdPV is a different stereochemical form, so results from KdPV studies should not be presented as direct evidence for all-L KPV.

What Cell Studies Reported

Intestinal Epithelial and T-Cell Models

Dalmasso and colleagues tested KPV in Caco2-BBE and HT29-Cl.19A intestinal epithelial cells and in Jurkat T cells. The study used NF-κB reporter assays, Western blots, RT-PCR, ELISA, and radiolabeled uptake tests.[3]

In IL-1β-stimulated Caco2-BBE cells, 10 nM KPV was linked to lower NF-κB reporter activity, slower IκB-α degradation, lower phosphorylation of ERK1/2, JNK, and p38, and lower IL-8 mRNA and secreted IL-8. These findings apply only to the cell type, stimulus, concentration, and timing used in that experiment.[3]

The same paper supported uptake through the PepT1 transporter. The effect was not seen in native HT29-Cl.19A cells that lacked PepT1, but it returned after the cells were made to express human PepT1.

Radiolabeled tests also showed KPV uptake in Caco2-BBE and Jurkat cells.[3]

The paper did not show an increase in IL-10 in its mouse experiments. For that reason, this article does not claim that KPV raises IL-10 or causes an M1-to-M2 macrophage shift.[3]

Bronchial Epithelial Cell Model

Land studied KPV in the 16HBE14o- bronchial epithelial cell line. Under the reported conditions, KPV was linked to lower NF-κB reporter activity, lower MMP-9 activity, and lower secretion of IL-8 and eotaxin.[4]

The same study found less movement of the NF-κB p65/RelA subunit into the nucleus. It also found an increase in both total and phosphorylated IκB-α.

This supports a change in IκB-α stability or degradation, but it does not prove that KPV reduces IKK-driven IκB-α phosphorylation.[4]

Land proposed that an importin-related process may help explain the lower nuclear movement of p65/RelA. A separate study by Fagerlund et al. showed that importin-α3 and importin-α4 are the main importin-α isoforms mediating TNF-α-stimulated NF-κB p50/p65 heterodimer translocation into the nucleus.

Importin-α3 directly binds to the nuclear localization signals of p50 and p65, with p50 binding to the N-terminal and p65 to the C-terminal NLS binding site. NF-κB binds to importin-α only when free of IκBα.

This gives background support for the importin-related idea, but neither paper proves that KPV directly binds one fixed site on importin-α3 in every cell type.[5]

What Mouse Studies Reported

Mouse-model limit: The findings in this section are not human data, veterinary instructions, or dosing guidance.

Dalmasso and colleagues also tested KPV in DSS- and TNBS-based mouse intestinal-injury models. The study reported changes in histology, colon measurements, myeloperoxidase activity, and selected cytokine mRNA.

In the DSS model, IL-6 and IL-12 mRNA were lower. In the TNBS model, IL-1β, IL-6, TNF-α, and IFN-γ mRNA were lower under the reported conditions.[3]

Kannengiesser and colleagues tested KPV in DSS and CD45RBhi transfer mouse models. The measured endpoints included body-weight change, tissue findings, and myeloperoxidase activity.

The study also used mice with a nonfunctional MC1R; results in those mice suggested that some effects might be partly independent of normal MC1R signaling, but the evidence was limited and was not consistent across all measured endpoints.[6]

Formulation Studies

Laroui and colleagues placed KPV-loaded nanoparticles (~400 nm) inside an alginate-and-chitosan gel for a mouse DSS model. The study demonstrated that the nanoparticle-and-gel system could deliver KPV at a concentration approximately 12,000-fold lower than free KPV in solution while producing similar changes in inflammatory and histological parameters.

This result belongs only to that nanoparticle-and-gel system and must not be used as a general dose conversion for unformulated KPV.[7]

Xiao and colleagues studied hyaluronic-acid-functionalized KPV nanoparticles (HA-KPV-NPs, ~272 nm diameter, KPV encapsulation 39.7 ± 3.6%, 16 μg/kg/day orally for 5 days) in a 3% DSS mouse model.

HA-KPV-NP-treated mice showed TNF-α mRNA levels not significantly different from healthy controls, HA-KPV-NP-treated colon histology (H&E) was morphologically closest to healthy controls—with intact epithelial layers and minimal inflammatory cell infiltration—and spleen weight and colon length in the HA-KPV-NP group were not significantly different from healthy controls.

Data from this engineered carrier should not be presented as if it came from unformulated KPV.[8]

How to Read a KPV COA

A COA describes one batch. It does not prove human safety, clinical effectiveness, veterinary suitability, or regulatory approval.

The EMA synthetic-peptide guideline (adopted December 2025, effective 1 June 2026) is written for regulated peptide products, not specifically for an RUO KPV reagent. It is still a useful technical reference because it treats molecular mass, amino-acid sequence, stereochemistry, counter-ion, purity, content, water, residual solvents, and microbial quality as separate checks that should be evaluated according to the intended use.[9]

COA item What it tells you What it does not prove by itself
HPLC The main chromatographic peak and related peaks under the stated method The exact amount of peptide in the vial, the full sequence, stereochemistry, sterility, or endotoxin status
LC-MS or MALDI-TOF Whether an observed ion matches the expected molecular mass Chromatographic purity or the absence of every structural or stereochemical impurity
Sequence confirmation Evidence from interpretable LC-MS/MS fragmentation, NMR, peptide mapping, Edman degradation, or another justified orthogonal method. Amino-acid analysis confirms amino-acid composition but does not independently confirm residue order or stereochemistry. Batch purity unless purity is tested separately; amino-acid analysis alone does not distinguish Lys-Pro-Val from other sequence orders containing the same residues or confirm D/L configuration
Peptide content or assay The amount of peptide relative to the total weighed material. The result should state the calculation basis (e.g., as-is, dry basis, anhydrous basis, counter-ion-free basis, or peptide-equivalent basis). Identity unless an identity test is also provided
Water and counter-ion Information needed to understand net content and correct concentration calculations Biological activity
Residual solvents The measured solvents covered by the stated method The absence of solvents or contaminants that were not tested
Endotoxin The endotoxin level measured by a specified method (report as EU/mg or EU/vial as appropriate). Relevant for cell-based, immune-readout, and animal-model studies, especially where NF-κB, IL-8, or TNF-α endpoints are measured. A low HPLC impurity level does not establish a low endotoxin level; the two must be tested separately.
Stereochemical / epimer control Evidence from a justified chiral or orthogonal method when differentiation from KdPV (D-Pro-containing) or other epimers is critical. Routine HPLC and intact-mass measurements may not reliably separate L-Pro from D-Pro. Standard reversed-phase HPLC purity; a single HPLC peak area does not confirm that all stereocenters are the intended L-configuration.

HPLC area percentage is not the same as total peptide content. A sample can have a high HPLC main-peak area and still contain water, acetate, TFA, other counter-ions, or residual solvent.

The COA should state the method and make clear whether the reported number is chromatographic purity or peptide content.

For sensitive cell-based or long-term animal studies, researchers should also consider whether synthesis-related impurities—such as residual metals, coupling reagents, scavenger residues, trifluoroacetic acid, residual solvents, or microbial load—may be relevant even when HPLC purity appears high. A single HPLC purity value does not establish that all of these variables have been controlled.

ICH Q3C(R9) is the current adopted ICH guideline for residual solvents in pharmaceuticals (Step 4, January 2024). It groups solvents by risk and explains when testing is linked to solvents used or formed during manufacture.

For an RUO peptide, it should be used as a technical reference rather than presented as proof that a batch meets a pharmaceutical-use standard.[10]

Laboratory Stock Preparation and Storage

Laboratory Configuration Only: The calculations below are for controlled in-vitro assay preparation by trained laboratory personnel. They are not human or veterinary dosing instructions.

For free-acid KPV with a molecular weight of 342.43 g/mol:

  • 1 mM = 0.34243 mg/mL
  • 10 mM = 3.4243 mg/mL (theoretical; see solubility note below)

mass concentration (mg/mL) = concentration (mM) × molecular weight (g/mol) ÷ 1000

These numbers apply only to free-acid KPV. Recalculate the amount when the batch is an acetate, TFA salt, hydrochloride, hydrate, solvate, modified peptide, or a material with a lot-specific peptide-content correction.

Solubility note: The 10 mM calculation (3.4243 mg/mL) is a mathematical conversion, not a solubility claim. A 10 mM aqueous stock may not be achievable for every chemical form, lot, pH, and diluent.

Published reference data on KPV aqueous solubility suggest that concentrations above approximately 2 mM may approach or exceed practically achievable limits for the free-acid form. Solubility must be verified experimentally for the specific chemical form, lot, pH, and diluent before preparing a working stock.

A visually clear solution does not confirm that the target concentration has been reached; where quantitative certainty is needed, researchers should consider centrifugation, filtration, and direct measurement such as HPLC or absorbance. Strong acids, strong bases, or high-percentage organic solvents should not be used to force dissolution without evaluating their effect on peptide stability and cell-assay compatibility.

Match the vehicle in every control condition.

Use a laboratory-grade diluent that has been checked for the selected cell assay. Start with a small solubility test at the required concentration.

This article does not provide instructions for syringes, injection water, bacteriostatic water, or any human or veterinary administration method.

Store the lyophilized material at −20°C, protected from light and moisture, unless the lot label or COA gives a different condition. For prepared stocks, use the stability period supported by the laboratory’s own method and container.

Make single-use aliquots where practical and avoid repeated freeze-thaw cycles. Do not claim a universal refrigerated shelf life without batch- and diluent-specific stability data.

Limits of the Evidence

  • The published evidence discussed here comes from cell studies and mouse models, not human use.
  • Results from free-acid KPV, KPV acetate, KdPV, modified KPV, and KPV-loaded nanoparticles must be kept separate.
  • A change in NF-κB, MAPK, cytokine, histology, or enzyme markers in one model does not prove the same result in another model.
  • The importin-related explanation is a proposed mechanism, not a universally proven direct binding event. Importin-α3 and importin-α4 have been identified as NF-κB nuclear transporters, but KPV has not been shown to directly bind a fixed site on importin-α3 in every cell type.
  • A COA is a batch-quality document. It does not show that the material is safe or effective for human, cosmetic, or veterinary use.

References

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, MSH (11–13). PubChem CID 125672.
  2. National Center for Biotechnology Information. PubChem Compound Summary for CID 90474670, L-lysyl-L-prolyl-L-valine acetate. PubChem CID 90474670.
  3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026. PubMed Central full text.
  4. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59–73. PubMed Central full text.
  5. Fagerlund R, Kinnunen L, Köhler M, Julkunen I, Melén K. NF-κB is transported into the nucleus by importin alpha3 and importin alpha4. J Biol Chem. 2005;280(16):15942–15951. doi:10.1074/jbc.M500814200. PubMed record.
  6. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324–331. doi:10.1002/ibd.20334. PubMed record.
  7. Laroui H, Dalmasso G, Nguyen HTT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843–853.e1–e2. doi:10.1053/j.gastro.2009.11.003. PubMed record.
  8. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628–1640. doi:10.1016/j.ymthe.2016.11.020. PubMed Central full text.
  9. European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides. EMA/CHMP/CVMP/QWP/367182/2025. Adopted December 2025; effective 1 June 2026. EMA final guideline.
  10. International Council for Harmonisation. ICH Q3C(R9): Impurities — Guideline for Residual Solvents. Step 4, January 2024. ICH Q3C(R9).

Research Use Only Disclaimer

Research Use Only: All SaiyanMed products are for laboratory research purposes only and not approved for human use. This article is provided for informational context regarding standard laboratory in-vitro/in-vivo research procedures only, and does not constitute medical, clinical, veterinary guidance or treatment advice.